Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RGS4 | P49798 | 6/20 | 0.40 |
| ▸ | RGS8 | P57771 | 6/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20548580 | 1.00 | LMNA (0.41) | LMNATP53MAPTRGS4RGS8 | |
| SCHEMBL20548415 | 0.80 | LMNA (0.41) | LMNAMAPTDAOKMT2AALDH1A1 | |
| SCHEMBL30314375 | 0.80 | LMNA (0.41) | LMNAMAPTDAOKMT2AALDH1A1 | |
| SCHEMBL20548652 | 0.79 | ALDH1A1 (0.50) | LMNATP53MAPTPKMDAO | |
| SCHEMBL30314486 | 0.79 | ALDH1A1 (0.50) | LMNATP53MAPTPKMDAO | |
| SCHEMBL29195780 | 0.79 | MAPT (0.45) | LMNATP53MAPTPKMKMT2A | |
| SCHEMBL20548443 | 0.77 | LMNA (0.39) | LMNADAOALDH1A1 | |
| SCHEMBL30314317 | 0.77 | LMNA (0.39) | LMNADAOALDH1A1 | |
| SCHEMBL20548546 | 0.71 | ALDH1A1 (0.50) | LMNATP53MAPTPKMDAO | |
| SCHEMBL30314431 | 0.71 | ALDH1A1 (0.50) | LMNATP53MAPTPKMDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | LMNA 2079/4885TP53 3999/4885MAPT 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.